Skip to main content
. 2018 Jun 1;156:38–45. doi: 10.1016/j.antiviral.2018.05.013

Fig. 3.

Fig. 3

PK analysis of plasma samples from uninfected hamsters dosed IP with escalating doses of galidesivir. Animals in each treatment group (n = 6) were treated with 50, 100, 150 or 200 mg/kg of galidesivir or the vehicle placebo (n = 3), by IP injection. Whole blood was collected at the designated times (Table 2) and arithmetic mean and standard deviation plasma concentrations and mean composite PK parameters (Table inset) are shown.